Nutritional management of growth faltering in infants aged under six months in Asia and Africa: study protocol for a multicentre randomised trial (BRANCH, BReAstfeediNg Counselling and management of growtH)

亚洲和非洲六个月以下婴儿生长发育迟缓的营养管理:一项多中心随机试验的研究方案(BRANCH,母乳喂养咨询和管理生长发育)

阅读:2

Abstract

BACKGROUND: Treatment of growth faltering in early infancy may improve short and long term child health outcomes. The overall aim of this trial is to determine, in infants who meet study criteria for growth faltering, the effect of intensive breastfeeding counselling and support (IBFCS) plus nutritional milk supplementation (NMS) compared with IBFCS alone, on mortality, morbidity and growth at 6 completed months in low resource settings in South Asia and Sub-Saharan Africa. The primary outcome of the trial is wasting free survival (alive without wasting (weight for length standard deviation score < - 2 standard deviations (SD))) at 6 completed months of age. METHODS: This is a multi-centre, parallel-group, individually-randomized, non-blinded, controlled trial implemented in seven countries: three in Asia (Bangladesh, India and Pakistan) and four in Africa (Ethiopia, Nigeria, Tanzania and Uganda). Eleven thousand (11,000) infants with a gestational age of at least 28 weeks are enrolled and individually randomised between 7 and 14 days of age. The mother of each infant receives breastfeeding support from trained peer counsellors. Research workers follow up each infant 1-2 weekly at the infant's home to collect growth and outcome data. If infants meet study criteria for growth problems (slow weight gain, growth concern or growth faltering) they are reviewed by study clinicians, their medical problems are treated, and their mothers receive IBFCS. Infants with growth faltering in the intervention arm also receive nutritional milk supplementation (NMS) (prescribed quantities of term infant formula that meets Codex Alimentarius standards calculated to fulfill the needs for catch up growth). The comparison group receives IBFCS alone. Weekly growth monitoring continues and final outcome data (mortality, wasting) are measured in all infants at 6 completed months. DISCUSSION: This large randomised trial will provide evidence about the role of NMS, if any, in infants with growth faltering who do not respond to IBFCS and treatment of medical problems in low resource settings. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry (ANZCTR) CTRN12624000704594. Registered on June 4 2024.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。